Targeting trypanothione metabolism in trypanosomatid human parasites.
The diseases caused by the trypanosomatid parasites Trypanosoma brucei, Trypanosoma cruzi and Leishmania are widely distributed throughout the world. Because of the toxic side-effects and the economically unviable cost of the currently used pharmaceutical treatments, the search for new drug targets continues. Since the antioxidant metabolism in these parasites relies on trypanothione [T(SH)(2)], a functional analog of glutathione, most of the pathway enzymes involved in its synthesis, utilization and reduction have been proposed as drug targets for therapeutic intervention. In the present review, the antioxidant metabolism and the phenotypic effects of inhibiting by genetic (RNA interference, knock-out) or chemical approaches, the T(SH)(2) and polyamine pathway enzymes in the parasites are analyzed. Although the genetic strategies are helpful in identifying essential genes for parasite survival/infectivity, they are less useful for drug-target validation. The effectiveness of targeting each pathway enzyme was evaluated by considering (i) the enzyme kinetic properties and antioxidant metabolite concentrations and (ii) the current knowledge and experimental approaches to the study of the control of fluxes and intermediary concentrations in metabolic pathways. The metabolic control analysis indicates that highly potent and specific inhibitors have to be designed for trypanothione reductase and the peroxide detoxification system, and hence other enzymes emerge (γ-glutamylcysteine synthetase, trypanothione synthetase, ornithine decarboxylase, S-adenosylmethionine decarboxylase and polyamine transporters) as alternative more suitable and effective drug targets in the antioxidant metabolism of trypanosomatids.
Olin-Sandoval
Viridiana
V
Departamento de Bioquímica, Instituto Nacional de Cardiología, México DF, 14080, México.
Moreno-Sánchez
Rafael
R
Saavedra
Emma
E
D000963:Antimetabolites / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000975:Antioxidants / Q000378:metabolism; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology*; D056986:Euglenozoa Infections / Q000188:drug therapy; D005978:Glutathione / Q000031:analogs & derivatives* / Q000378:metabolism; D006801:Humans; D058990:Molecular Targeted Therapy; D009247:NADH, NADPH Oxidoreductases / Q000037:antagonists & inhibitors / Q000502:physiology; D010545:Peroxides / Q000378:metabolism; D015800:Protozoan Proteins / Q000037:antagonists & inhibitors / Q000502:physiology; D013095:Spermidine / Q000031:analogs & derivatives* / Q000378:metabolism; D014344:Trypanocidal Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D014351:Trypanosomatina / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism*
D000963:Antimetabolites; D000975:Antioxidants; D004791:Enzyme Inhibitors; D010545:Peroxides; D015800:Protozoan Proteins; D014344:Trypanocidal Agents; C044809:trypanothione; D009247:NADH, NADPH Oxidoreductases; C049608:trypanothione reductase; D005978:Glutathione; D013095:Spermidine